Newron Pharmaceuticals SpA (SW:NWRN) — Market Cap & Net Worth
Market Cap & Net Worth: Newron Pharmaceuticals SpA (NWRN)
Newron Pharmaceuticals SpA (SW:NWRN) has a market capitalization of $297.11 Million (CHF235.00 Million) as of June 18, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #14986 globally and #155 in its home market, demonstrating a 1.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Newron Pharmaceuticals SpA's stock price CHF12.04 by its total outstanding shares 20805797 (20.81 Million). Review Newron Pharmaceuticals SpA total liabilities to assess the company's total debt and financial obligations.
Newron Pharmaceuticals SpA Market Cap History: 2015 to 2026
Newron Pharmaceuticals SpA's market capitalization history from 2015 to 2026. Data shows change from $673.39 Million to $316.70 Million (-8.06% CAGR).
Newron Pharmaceuticals SpA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Newron Pharmaceuticals SpA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
32.80x
Newron Pharmaceuticals SpA's market cap is 32.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $530.03 Million | $6.73 Million | -$15.24 Million | 78.80x | N/A |
| 2017 | $305.13 Million | $13.43 Million | -$5.28 Million | 22.72x | N/A |
| 2018 | $147.57 Million | $4.03 Million | -$15.04 Million | 36.66x | N/A |
| 2019 | $167.03 Million | $7.04 Million | -$20.21 Million | 23.73x | N/A |
| 2020 | $56.55 Million | $5.26 Million | -$21.00 Million | 10.76x | N/A |
| 2021 | $42.61 Million | $5.76 Million | -$14.90 Million | 7.40x | N/A |
| 2022 | $40.77 Million | $6.09 Million | -$17.49 Million | 6.69x | N/A |
| 2023 | $130.21 Million | $9.06 Million | -$16.22 Million | 14.38x | N/A |
| 2024 | $235.42 Million | $51.39 Million | $15.84 Million | 4.58x | 14.86x |
| 2025 | $627.35 Million | $19.13 Million | -$13.33 Million | 32.80x | N/A |
Competitor Companies of NWRN by Market Capitalization
Companies near Newron Pharmaceuticals SpA in the global market cap rankings as of June 18, 2026.
Key companies related to Newron Pharmaceuticals SpA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Newron Pharmaceuticals SpA Historical Marketcap From 2015 to 2026
Between 2015 and today, Newron Pharmaceuticals SpA's market cap moved from $673.39 Million to $ 316.70 Million, with a yearly change of -8.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF316.70 Million | -49.52% |
| 2025 | CHF627.35 Million | +166.48% |
| 2024 | CHF235.42 Million | +80.81% |
| 2023 | CHF130.21 Million | +219.35% |
| 2022 | CHF40.77 Million | -4.32% |
| 2021 | CHF42.61 Million | -24.65% |
| 2020 | CHF56.55 Million | -66.14% |
| 2019 | CHF167.03 Million | +13.19% |
| 2018 | CHF147.57 Million | -51.64% |
| 2017 | CHF305.13 Million | -42.43% |
| 2016 | CHF530.03 Million | -21.29% |
| 2015 | CHF673.39 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Newron Pharmaceuticals SpA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $297.11 Million USD |
| MoneyControl | $297.11 Million USD |
| MarketWatch | $297.11 Million USD |
| marketcap.company | $297.11 Million USD |
| Reuters | $297.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more